VIP is a neuropeptide produced by both neurons and immune cells that acts as a major immunoregulatory molecule, suppressing inflammation and showing therapeutic potential for autoimmune diseases.
Dual-source immunomodulatorVIP is produced by both neurons and immune cells themselves, creating a bidirectional communication system between the nervous and immune systems that maintains immune tolerance and controls inflammation.
What the researchers found
VIP is widely distributed in the central and peripheral nervous system and is also synthesized by immune cells, which express VIP receptors — creating an autocrine/paracrine immunoregulatory loop. VIP contributes to immune privilege in organs like the CNS (central nervous system) by maintaining immune deviation, and controls acute inflammation in peripheral immune organs.
The review summarizes VIP's broad immunomodulatory effects: it generally suppresses pro-inflammatory responses, shifts T cell differentiation toward regulatory phenotypes, and modulates cytokine production. Both endogenous VIP (naturally produced) and exogenous VIP (administered therapeutically) show potential in inflammatory and autoimmune disorders.
Why it matters
The nervous system and immune system are deeply interconnected, but the mechanisms of this communication are still being elucidated. VIP represents one of the clearest examples of a neuropeptide directly controlling immune function. Understanding this could lead to new treatments for autoimmune diseases like multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease — conditions where the immune system attacks the body's own tissues.
How the study worked
This is a comprehensive review article synthesizing current literature on VIP biology in the immune system. It covers VIP production by neurons and immune cells, VIP receptor expression and signaling, VIP effects on various immune cell types, and VIP's role in animal models and clinical observations of inflammatory and autoimmune diseases.
What this study cannot tell us
As a review article, this does not present new experimental data. Much of the evidence comes from animal models, and clinical translation of VIP-based therapies has been limited by VIP's short half-life and multiple biological effects. The review focuses on VIP's immunosuppressive properties, but VIP can have context-dependent effects that complicate therapeutic application. Specificity of VIP receptor targeting for therapeutic benefit without side effects remains a challenge.
How to read the evidence
This is a comprehensive review published in Acta Physiologica, synthesizing preclinical and limited clinical evidence. While it provides an excellent overview of VIP immunobiology, the therapeutic applications discussed remain largely preclinical.
When this study was published
Published in 2015, this review captures the state of VIP immunobiology knowledge at that time. VIP-based therapeutic approaches have continued to be explored, particularly with modified analogs that have improved pharmacokinetic properties.
The bigger picture
VIP exemplifies the emerging understanding that the nervous and immune systems are not separate but deeply integrated. The concept of 'neuroimmunology' — where neuropeptides modulate immune responses — has implications far beyond VIP, touching on stress-related immune dysfunction, neuroinflammation in neurodegenerative diseases, and the gut-brain axis. VIP's role in immune privilege also has implications for understanding why certain organs (brain, eyes, testes) tolerate foreign antigens differently.
Questions still open
- Can VIP analogs with improved stability be developed for clinical treatment of autoimmune diseases?
- How does VIP balance its immunosuppressive role with the need for immune defense against infections?
- Could VIP receptor agonists be used to restore immune privilege in organ transplantation?
Common questions
What is VIP and how does it affect the immune system?
Could VIP-based treatments help autoimmune diseases?
Read the original research
The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.
Acta physiologica (Oxford, England), 213(2), 442-52
Citation
Ganea, D; Hooper, K M; Kong, W. (2015). The neuropeptide vasoactive intestinal peptide: direct effects on immune cells and involvement in inflammatory and autoimmune diseases.. Acta physiologica (Oxford, England), 213(2), 442-52. https://doi.org/10.1111/apha.12427